Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.7679
+0.0169 (2.25%)
May 13, 2025, 4:00 PM - Market closed
Cue Biopharma Revenue
Cue Biopharma had revenue of $421.00K in the quarter ending March 31, 2025, a decrease of -75.48%. This brings the company's revenue in the last twelve months to $7.99M, up 13.83% year-over-year. In the year 2024, Cue Biopharma had annual revenue of $9.29M with 69.16% growth.
Revenue (ttm)
$7.99M
Revenue Growth
+13.83%
P/S Ratio
6.01
Revenue / Employee
$194,902
Employees
41
Market Cap
57.86M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.29M | 3.80M | 69.16% |
Dec 31, 2023 | 5.49M | 4.25M | 340.96% |
Dec 31, 2022 | 1.25M | -13.70M | -91.67% |
Dec 31, 2021 | 14.94M | 11.79M | 373.68% |
Dec 31, 2020 | 3.15M | -304.01K | -8.79% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CUE News
- 1 day ago - Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 days ago - Cue Biopharma to Host Virtual Investor Event on May 15, 2025 - GlobeNewsWire
- 8 days ago - Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference - GlobeNewsWire
- 4 weeks ago - Cue Biopharma, Inc. (CUE) Business Update Call (Transcript) - Seeking Alpha
- 4 weeks ago - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - GlobeNewsWire
- 4 weeks ago - Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Cue Biopharma Announces Proposed Public Offering - GlobeNewsWire
- 4 weeks ago - Cue Biopharma to Host Business Update Call and Webcast - GlobeNewsWire